Instil Bio (TIL)

Executive Summary

Instil Bio is a publicly traded biotechnology company focused on developing innovative cell therapies for solid tumors. Despite recent setbacks, including the termination of its lead candidate ITIL-168 in advanced melanoma and withdrawal in cervical cancer, the company is advancing two Phase 1 programs: ITIL-306 for epithelial ovarian cancer, non-small cell lung cancer, and renal cell carcinoma (NCT05397093), and AXN-2510 for adult solid tumors (NCT07159828). The company is led by an experienced team with a track record in biopharma. Near-term value inflection points depend on initial clinical data from these programs, which could validate the company's platform and pipeline.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 data readout for AXN-251030% success
• Q3 2026Clinical update for ITIL-306 at a medical conference40% success
• TBDPotential strategic partnership or licensing deal20% success